BSTG:OTC-Biostage, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 1.51

Change

-0.22 (-12.72)%

Market Cap

USD 0.02B

Volume

678.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-1.19 (-1.73%)

USD162.57B 24.98 2.76
CSLLY CSL Limited

+0.81 (+0.78%)

USD94.29B 42.48 24.49
CMXHF CSL Limited

N/A

USD94.17B 42.37 24.49
GNMSF Genmab A/S

+2.56 (+0.73%)

USD23.24B 28.18 3.06
UCBJF UCB SA

N/A

USD22.12B 24.73 18.77
UCBJY UCB SA

-0.67 (-1.15%)

USD21.92B 24.83 18.77
SBHMY Sino Biopharmaceutical Limited

+1.76 (+8.80%)

USD21.14B 47.10 3.58
SBMFF Sino Biopharmaceutical Limited

N/A

USD20.95B 52.75 3.58
PPTDF PeptiDream Inc

N/A

USD5.30B 260.99 1.36
MPSYF MorphoSys AG

N/A

USD4.23B 32.27 28.84

ETFs Containing BSTG

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.88% 28% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.88% 27% F 33% F
Trailing 12 Months  
Capital Gain -46.36% 21% F 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.36% 21% F 20% F
Trailing 5 Years  
Capital Gain 71.34% 74% C 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.34% 74% C 71% C-
Average Annual (5 Year Horizon)  
Capital Gain 318.37% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 318.37% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 856.40% N/A N/A N/A N/A
Risk Adjusted Return 37.18% N/A N/A N/A N/A
Market Capitalization 0.02B 52% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 53.62 12% F 4% F
Price / Cash Flow Ratio -2.50 49% F 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -735.56% 11% F 3% F
Return on Invested Capital -579.74% 6% F 2% F
Return on Assets -227.88% 17% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.35 22% F 25% F
Short Percent 6.77% 15% F 27% F
Beta -0.29 83% B 86% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.